News | Proton Therapy | September 18, 2025

First proton therapy system designed to fit into an existing LINAC vault, advancing access to high-quality proton therapy.

Mevion Medical Systems Receives FDA Clearance for Proton Beam Radiation Therapy System

Sept. 15, 2025 — Mevion Medical Systems  announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the MEVION S250-FIT Proton Beam Radiation Therapy System, marking a significant milestone in expanding access to proton therapy. 

The MEVION S250-FIT is the first proton therapy system designed to seamlessly fit into a standard radiation therapy vault. By leveraging existing infrastructure, the MEVION S250-FIT system lowers barriers for hospitals and cancer centers to adopt proton therapy, accelerating access and bringing advanced, high-quality proton therapy closer to patients worldwide.

The MEVION S250-FIT is currently under installation at Stanford Health Care and BayCare Health System, with additional installations beginning at Atlantic Health System and the University of Nebraska Medical Center. This momentum underscores how top-tier institutions are embracing the MEVION S250-FIT system as a future-ready, quality-driven solution, reaffirming Mevion’s role as the trusted partner of leading cancer centers.

“The FDA clearance of the MEVION S250-FIT marks the beginning of a new era in proton therapy. For more than two decades, Mevion has redefined proton therapy through audacious innovation -- from pioneering the world’s first compact, single-room system to now enabling proton therapy to fit into existing radiation therapy vaults, expanding access for patients worldwide. I am incredibly proud of the Mevion team and our partners at Leo Cancer Care for making this achievement possible and look forward to the impact of this innovation as centers like Stanford bring it to patients.” — Tina Yu, CEO and President of Mevion Medical Systems.

The MEVION S250-FIT system extends Mevion’s leadership in compact proton therapy by combining industry-leading precision, efficiency, and adaptability. Building on Mevion’s HYPERSCAN pencil beam scanning platform and introducing DirectArc proton arc therapy, the FIT system is also FLASH research ready, ensuring cancer centers gain advanced capabilities today while staying ready for future innovations.

For more information, please visit www.mevion.com.


Related Content

News | Enterprise Imaging

Mar. 9, 2026 — GE HealthCare recently announced that View, the viewer within the Genesis Radiology Workspace, has ...

Time March 12, 2026
arrow
News | Computed Tomography (CT)

March 5, 2026 — At ECR 2026, Royal Philips introduced Rembra, its next-generation radiology CT system designed for the ...

Time March 09, 2026
arrow
News | Magnetic Resonance Imaging (MRI)

March 4, 2026 — The U.S. Food and Drug Administration (FDA) has granted 510(k) clearance to Bayer for the expanded ...

Time March 04, 2026
arrow
News | Ultrasound Women's Health

March 2, 2026 — Ultrasound AI, a provider of artificial intelligence applications for medical imaging, has received FDA ...

Time March 03, 2026
arrow
News | Remote Viewing Systems

Feb. 26, 2026 — DeepHealth, Inc., a provider of AI-powered health informatics and a wholly owned subsidiary of RadNet ...

Time February 27, 2026
arrow
News | Contrast Media

Feb. 23, 2026 — Bracco, a global leader in diagnostic imaging, recently announced that the U.S. Food and Drug ...

Time February 24, 2026
arrow
News | Women's Health

Feb.23, 2026 — The first clinical patient received a Clairity Breast cancer risk score, marking a historic milestone in ...

Time February 23, 2026
arrow
News | Magnetic Resonance Imaging (MRI)

Feb. 19, 2026 — GE HealthCare recently announced 510(k) clearance of three new magnetic resonance (MR) innovations with ...

Time February 20, 2026
arrow
News | Magnetic Resonance Imaging (MRI)

Feb. 5, 2026 — Eyas Medical Imaging, Inc. has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its ...

Time February 06, 2026
arrow
News | Lung Imaging

Feb. 3, 2026 — RevealDx, a leader in the characterization of lung nodules, recently announced FDA clearance of RevealAI ...

Time February 04, 2026
arrow
Subscribe Now